| 曹樱花,徐小飞,王奎玲,赵晓辉,李广罡.神经节苷脂联合咪达唑仑治疗重症颅脑损伤的临床疗效及对患者血清MMP-9、GFAP、MBP、NSE水平的影响[J].现代生物医学进展英文版,2018,(19):3768-3771. |
| 神经节苷脂联合咪达唑仑治疗重症颅脑损伤的临床疗效及对患者血清MMP-9、GFAP、MBP、NSE水平的影响 |
| Curative Efficacy of Ganglioside Combined with Midazolamin in the Treatment of Severe Craniocerebral Injury and Its Effect on the Serum MMP-9, GFAP, MBP, NSE Levels |
| Received:June 23, 2018 Revised:July 18, 2018 |
| DOI：10.13241/j.cnki.pmb.2018.19.038 |
| 中文关键词: 神经节苷脂 咪达唑仑 重症颅脑损伤 基质金属蛋白酶-9 胶质纤维酸性蛋白 髓鞘碱性蛋白 神经元特异性烯醇化酶 |
| 英文关键词: Ganglioside Midazolam Severe craniocerebral injury Matrix metalloproteinase-9 Glial fibrillary acid protein Myelin basic protein Neuron-specific enolase |
| 基金项目:全军医药卫生科研基金项目(08MA014) |
|
| Hits: 523 |
| Download times: 197 |
| 中文摘要: |
| 摘要 目的：探讨神经节苷脂联合咪达唑仑治疗重症颅脑损伤的临床疗效及对患者血清基质金属蛋白酶-9(MMP-9)、胶质纤维酸性蛋白(GFAP)、髓鞘碱性蛋白(MBP)、神经元特异性烯醇化酶(NSE)水平的影响。方法：选择2016年3月到2017年9月于我院进行治疗的85例重症颅脑损伤患者，将其按随机数表法分为观察组(n=45)和对照组(n=40)，对照组使用神经节苷脂治疗，观察组采用神经节苷脂联合咪达唑仑治疗。比较两组治疗后疗效及血清GFAP、中枢神经特异蛋白(S100β)、NSE、MMP-9、MBP、C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)水平、格拉斯哥昏迷评分(Glasgow Coma Scale，GCS)评分的变化及不良反应的发生情况。结果：治疗后，观察组临床疗效总有效率(93.33%)显著高于对照组(75.00%，P＜0.05)；两组血清GFAP、S100β、NSE、MMP-9、MBP、CRP、IL-6及TNF-α水平均较治疗前明显下降，且观察组以上指标均显著低于对照组(P＜0.05)；观察组GCS评分明显高于对照组(P＜0.05)，且不良反应发生率明显低于对照组(6.67% vs. 30.00%，P<0.05)。结论：神经节苷脂联合咪达唑仑治疗重症颅脑损伤患者的临床效果显著，明显优于单用神经节苷脂治疗，可能与其有效改善患者血清MMP-9、GFAP、MBP、NSE水平及抑制炎症因子的生成有关。 |
| 英文摘要: |
| ABSTRACT Objective: To study the curative efficacy of ganglioside combined with midazolamin in the treatment of severe cranio- cerebral injury and its effect on the serum matrix metalloproteinase-9 (MMP-9), glial fibrillary acidic protein (GFAP), myelin basic pro- tein (MBP), neuron-specific enolase (NSE) levels. Methods: 85 cases of patients with severe craniocerebral injury treated in our hospital from March 2016 to September 2017 were selected, they were divided into the observation group (n=45) and the control group (n=40) ac- cording to the random number table. The control group was treated by ganglioside, and the observation group was treated by ganglioside combined with midazolam. After treatment, the curative effect, changes of serum GFAP, CNS, MMP-9, MBP, c-reactive protein (CRP), interleukin-6 (IL-6), TNF-α, Glasgow Coma Scale (GCS) levels before and after treatment and incidence of adverse reactions were com- pared between two groups. Results: After treatment, the total effective rate (93.33%) of observation group was significantly higher than that of the control group (75.00%)(P<0.05); the serum GFAP, S100 aspirate, NSE, MMP-9, MBP, CRP, IL-6 and TNF-α were signifi- cantly decreased in the two groups compared with those before treatment, and the above indicators in the observation group were signifi- cantly lower than those in the control group (P<0.05); The GCS score of observation group was significantly higher than that of the con- trol group (P<0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (6.67% vs. 30.00%, P<0.05). Conclusion: The clinical effect of ganglioside combined with midazolam was more effective than ganglio- side alone in the treatment of patients with severe craniocerebral injury, it may be related to the effective derease of serum levels of MMP-9, GFAP, MBP, and NSE. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
